Author

Jill O’Moore

McLaughlin Research Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Neuroscience· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:mouse· 3 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Deborah E. CabiniD· 3 shared Eric Vallabh MinikeliD· 3 shared Sonia M. VallabhiD· 3 shared George A. CarlsoniD· 2 shared Hien Tran ZhaoiD· 2 shared Jasna KrižiD· 2 shared Rose Pitstick· 2 shared Walker S. JacksoniD· 2 shared

Activity by Year

2020-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersNeuroscience

Deborah E. CabinORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

PrP turnover in vivo and the time to effect of prion disease therapeutics

Taylor L Corridon, Jill O’Moore, Alyssa Seerley, Daniel A. Sprague, Yuan Lian, Vanessa Laversenne, Briana Noble, Nikita G Kamath, Fiona E. Serack, Abdul Basit Shaikh, Brian Erickson, Craig R. Braun, Kendrick DeSouza-Lenz, Michael Howard, Nathan Chan, , Eric Vallabh Minikel

The paper measures PrP half-life in vivo and shows it limits the time to effect of PrP-lowering therapies, with implications for drug development and clinical trial design.

PLoS Pathogens · May 26, 2026Peer-reviewedNeuroscience

Therapeutic trial of anle138b in mouse models of genetic prion disease

Sonia M. Vallabh, Dan Zou, Rose Pitstick, Jill O’Moore, Janet Peters, Derek Silvius, Jasna Križ, Walker S. Jackson, George A. Carlson, Eric Vallabh Minikel, Deborah E. Cabin

This study tests anle138b in mouse models of prion disease, finding improved survival in RML strain models but no clear endpoints in genetic mutation models.

Journal of Virology · Jan 18, 2023Peer-reviewedNeuroscience

Prion protein lowering is a disease-modifying therapy across prion strains, disease stages, and endpoints

Eric Vallabh Minikel, Hien Tran Zhao, Jason Le, Jill O’Moore, Rose Pitstick, Samantha Graffam, George A. Carlson, Michael P. Kavanaugh, Jasna Križ, Jae Beom Kim, Jiyan Ma, Holger Wille, Judd M. Aiken, Deborah McKenzie, Katsumi Doh‐ura, , Sonia M. Vallabh

This study shows that lowering prion protein expression with ASOs is effective in treating prion disease across different strains, treatment times, and endpoints.

Nucleic Acids Research · Jul 13, 2020Peer-reviewedNeuroscience